Encentrio Therapeutics, Inc.

Encentrio Therapeutics, Inc. is a privately held biotechnology company headquartered at 1800 Owens St., San Francisco, California 94158. Public information about the company is limited almost entirely to securities filings: an SEC Form D notice of exempt offering (accession number 0001971101-23-000002) filed in 2023, which reported $400,000 in equity sold under Rule 506(b), and the associated aggregator listings that classify the issuer in the biotechnology industry.

The company is referenced in the Form D-related records alongside a slate of directors and executive officers, and its name appears as a tagged entity ("EncentrioTherapeuticsIncMember") within the XBRL taxonomy of Vir Biotechnology's Form 10-Q for the quarterly period ended June 30, 2024, with context dates of January 2023 and June 2023. The sources reviewed do not describe Encentrio's therapeutic focus, pipeline, technology, business model, customers, or headcount, and no company website was identified.

Traction

The only disclosed traction indicator is a reported $400,000 of equity sold in a 2023 Regulation D exempt offering. No clinical, product, revenue, or partnership milestones are documented in the sources.

Latest developments

The most recent public reference identified is the appearance of Encentrio Therapeutics, Inc. as a tagged entity in Vir Biotechnology's Form 10-Q for the quarter ended June 30, 2024, with reporting contexts dated January 2023 and June 2023. The underlying nature of that relationship is not described in the retrieved document text.